Omega-3 fatty acids effectively mitigate high-sensitivity C-reactive protein (hs-CRP) biomarker of inflammation in acute myocardial infarction patients: a randomized, double-blind, placebo-controlled clinical trial-Reference-Cited by-同舟云学术

Omega-3 fatty acids effectively mitigate high-sensitivity C-reactive protein (hs-CRP) biomarker of inflammation in acute myocardial infarction patients: a randomized, double-blind, placebo-controlled clinical trial

Published:2024-07-29 Issue: Volume: Page:
ISSN:0028-1298
Container-title:Naunyn-Schmiedeberg's Archives of Pharmacology
language:en
Short-container-title:Naunyn-Schmiedeberg's Arch Pharmacol

Author:

Ahmadi Mostafa,Askari Vahid Reza,Shahri Bahram,Mousavi Noghab Seyed Mahdiar,Jarahi Lida,Baradaran Rahimi Vafa

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s00210-024-03330-1.pdf

Reference44 articles.

1. Abdolahi M, Sarraf P, Javanbakht MH, Honarvar NM, Hatami M, Soveyd N, Tafakhori A, Sedighiyan M, Djalali M, Jafarieh A, Masoudian Y, Djalali M (2018) A novel combination of ω-3 fatty acids and nano-curcumin modulates interleukin-6 gene expression and high sensitivity C-reactive protein serum levels in patients with migraine: a randomized clinical trial study. CNS Neurol Disord Drug Targets 17:430–438

2. AbuMweis S, Jew S, Tayyem R, Agraib L (2018) Eicosapentaenoic acid and docosahexaenoic acid containing supplements modulate risk factors for cardiovascular disease: a meta-analysis of randomised placebo-control human clinical trials. J Hum Nutr Diet 31:67–84

3. Ajala ON, Everett BM (2020) Targeting inflammation to reduce residual cardiovascular risk. Curr Atheroscler Rep 22:66

4. Baradaran Rahimi V, Askari VR (2022) A mechanistic review on immunomodulatory effects of selective type two cannabinoid receptor β-caryophyllene. BioFactors (oxford, England) 48:857–882

5. Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Doyle RT Jr, Juliano RA, Jiao L, Granowitz C, Tardif JC, Ballantyne CM (2019) Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med 380:11–22